HLB Group Appoints Eunyeong Yang as President and Head of Global Business Development
Former CHA Bio Group CBO Joins HLB Group
Commercialization System Strengthened Ahead of FDA Approval for Rivoceranib and More
HLB Group has appointed Eunyeong Yang, former Chief Business Officer (CBO) at CHA Bio Group, as President and Head of Bio Business Development.
According to HLB Group, this appointment is part of a strategic shift from an R&D-focused approach to a commercialization-centric strategy. As President, Yang will oversee global technology licensing and acquisition, joint development, strategic alliances for major pipelines within HLB Group, as well as the establishment of global partnerships and the overall commercialization strategy at the commercial stage.
Yang graduated from the College of Pharmacy at Seoul National University. She holds pharmacist licenses in Korea and the U.S. states of Colorado, Florida, and Michigan. She previously managed product strategy and marketing at Roche Korea and Eli Lilly Korea, and also worked as a pharmacist at hospitals and pharmacies in the United States. After serving as Global Sales Head at Samsung Biologics, she took on the role of CBO and Vice President at CHA Bio Group from 2022, leading business development for CHA Biotech, CHA Vaccine Institute, and CMG Pharmaceutical.
Hot Picks Today
"Ruined Because of Korea" Even with a Sharp Rally, No One Buys... Japanese Market Sways with KOSPI
- '1,670,000 Won to 1,170,000 Won': SK hynix Hits Lower Limit Shock, Pre-market Opening Price Controversy
- "Don't Be Sad, Mom Was Very Happy"... Son Battling Illness for Life Saves Four Before Passing Away
- Seoul’s 39-Degree ‘Extreme Heat’ Is Just the Beginning... Experts Warn: “It Will Persist Until 2050”
- "Unsettled by Korean Goods, Just Throw Them Away" — Japanese Netizens Respond with Harsh Comments to Relief Supplies
Moon Jeonghwan, Vice Chairman of Strategic Planning at HLB Group, stated, "With regulatory approvals for major pipelines such as the rivoceranib–camrelizumab combination therapy expected in July and lirafugratinib in September, HLB Group is at a critical juncture where we must translate R&D achievements into tangible business outcomes. President Yang is an expert in business development and global sales in the pharmaceutical and biotech industries both domestically and internationally, and we expect her to play a key role in advancing our commercialization strategy and expanding global collaboration opportunities."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
